Phase 2 N=49 Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer
Prostate Cancer
Primary: Best Overall PSA Response — 8; 20; 65 percentage of participatns
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=10 Fulvestrant in Hormone Refractory Prostate Cancer
Prostatic Neoplasms · Prostate Cancer
Primary: PSA Reduction ≥ 50% — 0 participants
Phase 2 N=35 RAD001 in Patients With Metastatic, Hormone-Refractory Prostate Cancer
Hormone Refractory Prostate Cancer
Primary: Biochemical Response Rate — 0 participants
Phase 2 N=71 Study of MDX-010 in Patients With Metastatic Hormone-Refractory Prostate Cancer
Prostate Cancer · Neoplasm Metastasis
Primary: Number of Participants With Serious AEs (SAEs), Adverse Events (AEs) Leading to Discontinuation, and Immune-related AEs - Treated Participants — 3; 2; 9; 2 participants
N/A N=20 Cabozantinib-S-Malate in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Change in PET Standard Uptake Value SUV Levels Pre-treatment to Post-treatment. — -56 percentage change from baseline
Phase 2 N=108 Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy
Prostate Cancer
Primary: Objective Prostate Specific Antigen (PSA) Response Rate Based on Bubley Criteria — 16.2; 52.4; 29.5; 1.9 Percentage of Participants
Phase 2 N=18 Hsp90 Inhibitor STA-9090 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: PFS Proportion Achieved With STA-9090 in Men With CRPC Who Have Received Prior Docetaxel Based Therapy — 0.0 proportion with 6+ months PFS
Phase 3 N=755 XRP6258 Plus Prednisone Compared to Mitoxantrone Plus Prednisone in Hormone Refractory Metastatic Prostate Cancer
Neoplasms · Prostatic Neoplasms
Primary: Overall Survival — 12.7; 15.1 Months — p=<0.0001
Phase 2 N=65 Combined Antiinflammatory and Angiostatic Therapy in Patients With Hormone-refractory Prostate Cancer
Prostate Cancer
Primary: PSA Response Rate — 38; 23 participants
Phase 2 N=90 The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Prostate Cancer
Primary: Change From Baseline in Functional Assessment of Cancer Therapy - Prostate (FACT-P) Total Score at 12 Months — -8.04; -6.60; -9.42 Units on a scale
Phase 1 N=27 A Phase 1 Study of MDV3100 in Patients With Castration-Resistant (Hormone-Refractory) Prostate Cancer
Prostate Cancer · Hormone Refractory Prostate Cancer
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (SAEs) — 0; 6; 14; 8 Participants
Phase 2 N=32 Phase II Study of Adenovirus/PSA Vaccine in Men With Hormone - Refractory Prostate Cancer
Hormone Refractory Prostate Cancer
Primary: Number of Participants With Stable, Decreased, or Increased PSA Doubling Times (PSADT) — 7; 2; 17 Participants
Phase 2 N=18 Sorafenib and Docetaxel in Patients With Prostate Cancer That Did Not Respond to Previous Hormone Therapy
Prostate Cancer
Primary: Prostate Specific Antigen (PSA) Response Rate — 6 Participants
Phase 2 N=41 Vinflunine in Hormone Refractory Prostate Cancer (HRPC)
Prostate Cancer
Primary: Protein-specific Antigen (PSA) Response Rate — 3 percentage of patients
Phase 2 N=86 E3-Hormone Refractory Prostrate Cancer Taxotere Combination
Prostate Cancer · Metastatic · Hormone Refractory
Primary: Prostate Specific Antigen (PSA) Response — 17; 29 Participants
Phase 2 N=28 AZD0530 in Treating Patients With Prostate Cancer That Did Not Respond to Hormone Therapy
Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: PSA Response Rate — 0 percentage of participants
Phase 2 N=47 Oxaliplatin and Pemetrexed Disodium in Treating Patients With Refractory Hormone-Resistant Prostate Cancer
Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Best Overall Response — 0; 14; 21; 8 Participants
Phase 2 N=204 Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC)
Prostatic Neoplasms
Primary: Percentage of Participants With Prostate Specific Antigen (PSA) Best Response — 51.7; 60.2; 28.1 Percentage of participants
Phase 2 N=30 Abiraterone Acetate in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Hormone-Resistant Prostate Cancer · Metastatic Prostate Carcinoma · Recurrent Prostate Carcinoma
Primary: Change in Tissue Testosterone and Dihydrotestosterone — 0.156 pg/mg
Phase 2 N=170 Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer
Castration Levels of Testosterone · Castration-Resistant Prostate Carcinoma · Lymphadenopathy
Primary: Maximum Tolerated Dosage (MTD) of Cabazitaxel-carboplatin in the Phase I Portion of Study — 25 mg/m^2
Phase 2 N=121 Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Adenocarcinoma of the Prostate · Hormone-refractory Prostate Cancer · Recurrent Prostate Cancer
Primary: Proportion of Patients With PSA Response — 0.293; 0.098; 0.042 Proportion of participants
Phase 3 N=1,432 Study on Prolonging Bone Metastasis-Free Survival in Men With Hormone Refractory Prostate Cancer
Hormone Refractory Prostate Cancer
Primary: Bone Metastasis-free Survival — 768.0; 897.00 days — p=0.0284
Phase 2 N=62 S0354, Anti-IL-6 Chimeric Monoclonal Antibody in Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
Prostate Cancer
Primary: Confirmed Prostate-Specific Antigen (PSA) Response — 3.8 percentage of participants
Phase 2 N=33 Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer
Prostate Neoplasms
Primary: Phase 1: Maximum Tolerated Dose (MTD) of Abiraterone Acetate — NA mg/day
Phase 2 N=10 Ipilimumab in Combination With Androgen Suppression Therapy in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Adenocarcinoma of the Prostate · Hormone-resistant Prostate Cancer · Recurrent Prostate Cancer
Primary: Percentage of Patients Who Achieve an Undetectable PSA (=< 0.2 ng/ml) — 0.0 percentage of patients
Phase 2 N=112 Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer
Prostate Adenocarcinoma · Prostate Carcinoma · Recurrent Prostate Carcinoma
Primary: Number of Participants Progression-free at 18 Months — 0 participants
Phase 2 N=7 Pertuzumab, Trastuzumab, Hyaluronidase-zzxf and Enzalutamide for Treatment of Metastatic Castration-Resistant Prostate Cancer
Castration-Resistant Prostate Carcinoma · Stage IVB Prostate Cancer AJCC v8
Primary: Overall Response Rate (ORR) — 50 percentage of participants
Phase 2 N=22 Cediranib Maleate With or Without Dasatinib in Patients With HRPC-Resistant to Treatment With Docetaxel
Hormone Refractory Prostate Cancer · Recurrent Prostate Cancer
Primary: 12-week Progression-free Survival as Per the Prostate Cancer Clinical Trials Working Group (PCWG2) — 2; 8 participants
Phase 2 N=154 A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer
Prostate Cancer
Primary: Progression-free Survival (PFS) in Participants With Hormone Refractory Prostate Cancer (HRPC) Administered LY2181308 Sodium Plus Docetaxel Compared to Docetaxel Alone…
Phase 2 N=27 Postoperative Radiation Therapy, Hormonal Therapy and Concurrent Docetaxel for High Risk Pathologic Prostate Cancer
Prostate Cancer
Primary: Percentage of Patients Who Can Safely Tolerate and Complete Adjuvant Hormonal Therapy, Radiation Therapy and Docetaxel After a Radical Prostatectomy — 26 percentage of…